|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 72-year-old man with a history of T1cN0M0 prostate adenocarcinoma and rising prostate-specific antigen underwent a fluciclovine PET/CT scan that showed high uptake in several para-aortic nodes, suspicious for prostate cancer.
|
31652158 |
2020 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Radiation dose-response (a Bayesian model) in the radiotherapy of the localized prostatic adenocarcinoma: the reliability of PSA slope changes as a response surrogate endpoint.
|
31304057 |
2019 |
|
Adenocarcinoma of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We present the case of a 71-year-old man with Gleason 3 + 3 = 6 pT2N0MxR0 adenocarcinoma of the prostate who presented with rising PSA level 16 years after radical prostatectomy.
|
30789396 |
2019 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
GETUG-AFU 16 was an open-label, multicentre, phase 3, randomised, controlled trial that enrolled men (aged ≥18 years) with Eastern Cooperative Oncology Group performance status of 0 or 1, with histologically confirmed adenocarcinoma of the prostate (but no previous androgen suppression or pelvic radiotherapy), stage pT2, T3, or T4a (bladder neck involvement only) and pN0 or pNx according to the tumour, node, metastasis (TNM) staging system, whose prostate-specific antigen (PSA) concentration increased from 0·1 ng/mL to between 0·2 ng/mL and 2·0 ng/mL after radical prostatectomy, without evidence of clinical disease.
|
31629656 |
2019 |
|
Adenocarcinoma of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 78-year-old man with biochemically recurrent prostate adenocarcinoma (prostate-specific antigen, 2.3 ng/mL) but without detectable disease in the chest, abdomen, or pelvis at conventional CT imaging or in the bones at Tc-MDP scintigraphy underwent F-fluciclovine (anti-1-amino-3-F-fluorocyclobutane-1-carboxylic acid) PET/CT to evaluate for occult recurrent or metastatic disease.
|
31107759 |
2019 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
A 73-year-old man underwent a Ga-PSMA-HBED-CC 11 PET/CT for evaluation of rising PSA in the context of previous radical retropubic prostatectomy and salvage radiotherapy for prostatic adenocarcinoma.
|
31162264 |
2019 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
COX-2 expression in PC was positively correlated with advanced patient age (p = <0.001), high level of PSA (p = 0.016), advanced D'Amico risk group (p = 0.038).
|
30402808 |
2019 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
PSA screened prostatic adenocarcinoma patients had a better prognosis in both overall and prostate cancer-specific survivals.
|
29416625 |
2018 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In contrast, p63- PC showed AR and PSA positive expression in all 15 samples.
|
29894516 |
2018 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Prostate-specific antigen (PSA) declines meeting >30%, >50%, and >90% criteria from baseline were observed in 64/57/29% of NEPC patients (n = 14) treated with platinum chemotherapy vs. 48/30/14% of men with prostate adenocarcinoma (n = 50), respectively.
|
29230006 |
2018 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
His presenting prostate-specific antigen (PSA) was 100 ng/mL, and a biopsy revealed Gleason 4+4 prostate adenocarcinoma.
|
29212868 |
2017 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Men (N=1554) with adenocarcinoma of the prostate (cT2c-T4, N0-Nx) with a prostate-specific antigen (PSA) <150 ng/mL and no evidence of distant metastasis were randomized (June 1992 to April 1995) to short-term ADT (STAD: 4 months of flutamide 250 mg 3 times per day and goserelin 3.6 mg per month) and definitive RT versus long-term ADT (LTAD: STAD with definitive RT plus an additional 24 months of monthly goserelin).
|
28463149 |
2017 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our goal is to evaluate the performance of PSMA and NKX3.1 and compare them with those of prostate-specific antigen (PSA) and prostate specific alkaline phosphatase (PSAP) in the cytological diagnosis of metPA MATERIALS: Cytology specimens from patients with a history of prostate adenocarcinoma at our institution between January 01, 2005 and December 31, 2015 were retrieved.
|
28888085 |
2017 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Compounds 2 and 5 were proven to be androgen receptor antagonists due to their binding activities for androgen receptors (IC50 280 and 160 μM, respectively) and the inhibitory activity of androgen-induced expression of prostate-specific antigen (PSA) mRNA in LNCaP (prostate adenocarcinoma) cells (IC50 20 and 18 μM, respectively).
|
23402539 |
2013 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
His serum PSA level was 4.9 ng/ml and a six-core biopsy revealed the presence of a prostate adenocarcinoma with a Gleason score of 7 (3+4).
|
23318356 |
2013 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
LNCaP cells express AR and PSA and their growth is inhibited by androgen withdrawal, similar to human prostatic adenocarcinoma.
|
21432867 |
2011 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Quantification of PSA mRNA levels in peripheral blood of patients with localized prostate adenocarcinoma before, during, and after radical prostatectomy by quantitative real-time PCR (qRT-PCR).
|
18584300 |
2009 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse.
|
18497543 |
2008 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the PCa tissue, no significant correlation was found between JUN immunohistochemical expression and tumor histologic grade (Gleason score) or serum prostate-specific antigen level.
|
16413376 |
2006 |
|
Adenocarcinoma of prostate
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this article, we report a case of adenocarcinoma of the prostate in a 56-year-old man with Klinefelter syndrome (47,XXY) and non-Hodgkin lymphoma, as well as the AR and PSA genotype.
|
15350307 |
2004 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
To evaluate whether the pretreatment determination of serum chromogranin A (CgA) can provide information beyond that obtained with serum prostate specific antigen (PSA) and Gleason score at biopsy as a predictive factor of clinical understaging (T2-pT3) of prostate adenocarcinoma.
|
14968443 |
2004 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We reported recently the induction of androgen-dependent iodide uptake activity in the human prostatic adenocarcinoma cell line LNCaP using a prostate-specific antigen (PSA) promoter-directed expression of the sodium iodide symporter (NIS) gene.
|
12865321 |
2003 |
|
Adenocarcinoma of prostate
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The mRNA expression for PSA in prostate adenocarcinoma biopsies was highly variable, ranging from 2 x 10(4) to 2.1 x 10(8) molecules/microg total RNA with a mean value of 2.5 x 10(7) and significantly higher (p = 0.006) than that found in BPH patients (mean: 1.3 x 10(6) and range: 6.9 x 10(2) to 8 x 10(6)).
|
12705330 |
2003 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data revealed that, serum PSA was superior to sE-cadherin as a marker for PC with a sensitivity of 83% compared to 59% in case of E-cadherin at the same specificity (96.6%).
|
10667479 |
1999 |
|
Adenocarcinoma of prostate
|
0.100 |
Biomarker
|
disease |
BEFREE |
KLK3 or prostate specific antigen (PSA) is a serine protease, which is an established tumour marker of prostatic adenocarcinoma.
|
10188912 |
1999 |